Motavizumab for Respiratory Syncytial Virus Treatment
Links shared publicly online about this topic
Respiratory Syncytial Virus (RSV) Infection: Follow-up - eMedicine Pediatrics: General Medicine
emedicine.medscape.com — “Followup: Respiratory syncytial virus (RSV) infection, which manifests primarily as bronchiolitis and/or viral pneumonia,1 is the leading cause of lower respiratory tract (LRT) infection in infants and young children. The clinical entity of bronchiolitis was described ...” View full resource at emedicine.medscape.com
Most Recently Shared on February 22, 2010 at 10:49 pm By:
Medscape Pediatrics Health Site and Pediatrics
Motavizumab or palivizumab? New info added to the eMedicine article Respiratory Syncytial Virus Infection (RSV). http://bit.ly/dcE6cQ
AstraZeneca withdraws BLA for motavizumab for serious respiratory syncytial virus (RSV) - ONA
oncologynurseadvisor.com — “AstraZeneca announced it has discontinued further development of motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 21, 2010 at 8:08 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
AstraZeneca withdraws BLA for motavizumab for serious respiratory syncytial virus (RSV) http://goo.gl/fb/Z6FA6
AstraZeneca withdraws BLA for motavizumab for serious respiratory syncytial virus (RSV) - MPR
empr.com — “AstraZeneca announced it has discontinued further development of motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease.” View full resource at empr.com
Most Recently Shared on December 21, 2010 at 7:46 pm By:
MPR News: AstraZeneca withdraws BLA for motavizumab for serious respiratory syncytial virus (RSV): AstraZeneca a... http://bit.ly/gpwn3w
Respiratory Syncytial Virus (RSV) - St. Louis Children's Hospital
stlouischildrens.org — “Detailed information on respiratory syncytial virus, including causes, symptoms, diagnosis, treatment, and prevention” View full resource at stlouischildrens.org
Most Recently Shared on February 10, 2010 at 5:30 pm By:
SLCH Answer Line Children's Hospital and Hospital
Why can RSV (Respiratory Syncytial Virus) be dangerous for infants? How to protect your baby + prevent its occurrence? http://bit.ly/alKoA2
Pediatrics Medical News about Motavizumab
mdlinx.com — “Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial” View full resource at mdlinx.com
Most Recently Shared on January 8, 2010 at 11:14 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Peds: Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial: Pediatr http://url4.eu/14lXt
Discovery in Lungs May Lead to Treatment for Respiratory Virus:
health.msn.com — “Discovery in Lungs May Lead to Treatment for Respiratory Virus:” View full resource at health.msn.com
Most Recently Shared on December 24, 2009 at 7:34 pm By:
Discovery in Lungs May Lead to Treatment for Respiratory Virus: http://bit.ly/5YoZB1
MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus
news-medical.net — “MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.” View full resource at news-medical.net
Most Recently Shared on November 10, 2009 at 10:13 am By:
Asthma News: MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncyti.. http://bit.ly/mHRQH
Respiratory Infections Caused By Respiratory Syncytial Virus: Almost 200,000 Children Under-5 Could Be Dying Each Year
medicalnewstoday.com — “An article published Online First and in an upcoming edition of The Lancet reports that up to 200,000 children under-5 could be dying each year due to acute lower-respiratory tract infectio” View full resource at medicalnewstoday.com
Most Recently Shared on April 16, 2010 at 12:13 pm By:
Respiratory Infections Caused By Respiratory Syncytial Virus: Almost 200,000 Children Under-5 Could Be Dying Each Year http://mnt.to/3Bkf
Medimmune Receives Complete Response Letter On Motavizumab
drugs.com — “Motavizumab is a new drug in development for the prevention of serious respiratory syncytial virus (RSV) disease. Motavizumab information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on September 8, 2010 at 12:40 am By:
Drugs and Devices OW OW Health
Medimmune Receives Complete Response Letter On Motavizumab: AstraZeneca today announced that MedImmune, its b... http://bit.ly/cIR0Es #drug
Infectious Dis. Medical News about Motavizumab
mdlinx.com — “Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial” View full resource at mdlinx.com
Most Recently Shared on January 9, 2010 at 1:23 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
I/D Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial.. http://bit.ly/5vbzUc
Experimental drug may offer more protection from RSV - Related Stories - AAP SmartBrief
smartbrief.com — “Researchers reported in Pediatrics that the investigational drug motavizumab may protect children at high risk for respiratory syncytial virus better than palivizumab. Study data showed motavizumab reduc” View full resource at smartbrief.com
Most Recently Shared on December 18, 2009 at 4:42 am By:
Clara Song Pediatrician, Physician, and Doctor
Experimental drug may offer more protection from RSV http://sbne.ws/r/3tF5
Alnylam Initiates Phase IIb Clinical Trial Of ALN-RSV01 In Adult Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Infection
medicalnewstoday.com — “Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi” View full resource at medicalnewstoday.com
Most Recently Shared on February 24, 2010 at 3:08 pm By:
Alnylam Initiates Phase IIb Clinical Trial Of ALN-RSV01 In Adult Lung Transplant Patients Infected With Respiratory Sy... http://mnt.to/3y3j
Alnylam Publishes Results from Phase IIa Study of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus Infection in Lung Transplant Patients - Drugs.com MedNews
drugs.com — “Sep 29, 2010 - Alnylam Pharmaceuticals, Inc. (Nasdaq ALNY), a leading RNAi therapeutics company announced today that it has published results in the American Jo” View full resource at drugs.com
Most Recently Shared on September 29, 2010 at 3:10 pm By:
Drugs and Devices OW OW Health
Alnylam Publishes Results from Phase IIa Study of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus I... http://bit.ly/aqlpaW #drug
FDA Advisory Committee Reviews MedImmune's Motavizumab
medicalnewstoday.com — “MedImmune announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regar” View full resource at medicalnewstoday.com
Most Recently Shared on June 3, 2010 at 1:13 pm By:
MNT Pharma News Health News and Pharma
FDA Advisory Committee Reviews MedImmune's Motavizumab http://mnt.to/3DrN #pharma #pharmaceutical
Discovery in Lungs May Lead to Treatment for Respiratory Virus - Drugs.com MedNews
drugs.com — “A lipid found in the lungs appears to have the ability to prevent infection with respiratory syncytial virus (RSV), which is a major cause of infection in babie” View full resource at drugs.com
Most Recently Shared on December 25, 2009 at 11:51 pm By:
Discovery in Lungs May Lead to Treatment for Respiratory Virus - http://bit.ly/6VaBad
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Medscape Pediatrics
Latest medical news, articles, and features from Medscape Pediatrics
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
